Q2 EPS Estimates for Legend Biotech Boosted by HC Wainwright

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Research analysts at HC Wainwright increased their Q2 2026 earnings estimates for shares of Legend Biotech in a research note issued to investors on Wednesday, July 15th. HC Wainwright analyst M. Kapoor now expects that the company will earn $0.22 per share for the quarter, up from their previous forecast of $0.18. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($0.01) per share. HC Wainwright also issued estimates for Legend Biotech’s Q3 2026 earnings at $0.16 EPS.

Legend Biotech (NASDAQ:LEGN) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The business had revenue of $305.10 million for the quarter, compared to analyst estimates of $306.51 million. Legend Biotech had a negative return on equity of 24.92% and a negative net margin of 21.98%.The firm’s revenue for the quarter was up 56.5% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.07) EPS.

Other equities analysts have also recently issued research reports about the company. Truist Financial cut Legend Biotech from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 20th. UBS Group increased their price objective on Legend Biotech from $31.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, June 3rd. JPMorgan Chase & Co. initiated coverage on Legend Biotech in a research note on Monday, July 13th. They issued a “neutral” rating and a $35.00 target price on the stock. Royal Bank Of Canada dropped their target price on Legend Biotech from $64.00 to $63.00 and set an “outperform” rating on the stock in a report on Tuesday, July 7th. Finally, TD Cowen upped their price target on Legend Biotech to $29.00 and gave the stock a “hold” rating in a research note on Wednesday, May 13th. Nine research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.00.

Legend Biotech Stock Performance

Shares of NASDAQ:LEGN opened at $22.26 on Thursday. The company has a 50-day simple moving average of $29.33 and a 200-day simple moving average of $23.32. Legend Biotech has a one year low of $16.24 and a one year high of $45.30. The stock has a market capitalization of $4.13 billion, a price-to-earnings ratio of -32.73 and a beta of 0.34.

Insiders Place Their Bets

In other Legend Biotech news, CEO Ying Huang sold 5,566 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $14.78, for a total transaction of $82,265.48. Following the transaction, the chief executive officer owned 241,872 shares in the company, valued at approximately $3,574,868.16. The trade was a 2.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.02% of the company’s stock.

Institutional Trading of Legend Biotech

A number of institutional investors have recently modified their holdings of the business. Suvretta Capital Management LLC grew its holdings in Legend Biotech by 73.1% during the fourth quarter. Suvretta Capital Management LLC now owns 6,608,629 shares of the company’s stock worth $143,672,000 after acquiring an additional 2,790,620 shares during the period. Westfield Capital Management Co. LP lifted its holdings in Legend Biotech by 1.2% in the fourth quarter. Westfield Capital Management Co. LP now owns 6,164,677 shares of the company’s stock valued at $134,020,000 after acquiring an additional 70,191 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Legend Biotech by 120.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,174,535 shares of the company’s stock worth $47,274,000 after purchasing an additional 1,188,449 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Legend Biotech during the 2nd quarter worth $55,307,000. Finally, Alliancebernstein L.P. boosted its position in shares of Legend Biotech by 4.6% during the 3rd quarter. Alliancebernstein L.P. now owns 1,632,967 shares of the company’s stock worth $53,251,000 after purchasing an additional 72,371 shares in the last quarter. 70.89% of the stock is currently owned by hedge funds and other institutional investors.

Legend Biotech Company Profile

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.